Expanding Early Detection of Prostate Cancer: What Men at High Risk Need to Know

Table of Contents

• Key Points
• Background: Why Prostate Cancer Screening Needs to Change
• Who Is at High Risk for Prostate Cancer?
• Current Gaps in Prostate Cancer Care
• Recommendations: How Early Detection Should Be Expanded
• What a Structured Screening Pathway Looks Like
• Conclusions: A Coordinated Call to Action
• What This Study Could Not Answer
• What This Means for You: Practical Steps
• Frequently Asked Questions
• Source Information

Key Points

• 57% of prostate cancer risk comes from inherited genetic factors, making genetic testing and risk-stratified screening urgent.
• 37% of dangerous genetic mutations occurred in men with no family history, so family history alone misses many carriers.
• Men of African ancestry have a 2.18-fold higher genetic risk; Ashkenazi Jewish men have highest germline variant prevalence.
• High-risk screening should start at age 40 for PGV carriers or 45 with strong family history, using annual PSA and mpMRI.
• A negative genetic test does not cancel a strong family history; family history remains an independent risk factor.

Background: Why Prostate Cancer Screening Needs to Change

Prostate cancer (PCa) is a major global health challenge, and the way we currently screen for it is not working well for everyone. Widespread opportunistic screening — meaning PSA blood tests done without a formal, organized program — has led to overdiagnosis and overtreatment, especially in men over 70 years old. This creates unnecessary health-care costs and burdens patients with treatments they may not need, while only providing a limited improvement in cancer-specific survival for the general population.

The problem is especially serious for men at elevated risk. Current screening strategies fail to adequately identify individuals with heritable risk — risk passed down through families and genes. The authors of this paper argue that a structured, risk-adapted approach is essential for two main reasons:

1. To minimize overdiagnosis and overtreatment in men with low prostate cancer risk
2. To improve early detection and survival in men with high prostate cancer risk

This is not a new idea in cancer care. Risk-adapted strategies have already been successfully implemented for breast and ovarian cancer, where genetic testing and tailored screening are standard practice. Prostate cancer has lagged behind, despite clear guideline recommendations. The authors note that 57% of prostate cancer risk is attributable to inherited genetic factors, making the case for genetic testing and risk-stratified screening all the more urgent.

Who Is at High Risk for Prostate Cancer?

Prostate cancer risk is multifactorial, meaning many factors combine to determine a man's overall risk. The primary risk factors well established in the medical literature include age, family history, hereditary syndromes, and ancestry. Each contributes differently, and understanding all of them is key to identifying who needs earlier or more intensive screening.

Family History: The Strongest Clinical Clue

Family history is a powerful predictor. It has been linked to a higher risk of high-grade prostate cancer (more aggressive disease) and earlier onset of the disease. The highest risk is seen in men whose first-degree relatives (father, brother, or son) have been affected by prostate cancer. Interestingly, the risk is inversely related to the age at which the family member was diagnosed — meaning if your father or brother was diagnosed young, your own risk is even higher.

One often-overlooked finding is that a family history of breast, ovarian, or colorectal cancer also raises a man's prostate cancer risk. This is because these cancers share overlapping genetic variants, particularly in DNA repair and mismatch repair pathways — the same genes that, when mutated, can predispose to multiple cancer types.

Inherited Genetic Variants (Pathogenic Germline Variants, or PGVs)

Familial prostate cancer risk is driven in large part by inherited genetic mutations called pathogenic germline variants (PGVs). The key genes involved include DNA repair genes such as BRCA1, BRCA2, HOXB13, ATM, CHEK2, PALB2, TP53, RAD51, and NBN, as well as the mismatch repair genes associated with Lynch syndrome: MLH1, MSH2, MSH6, PMS2, and EPCAM.

Some genes carry more weight than others. Mutations in BRCA2 and HOXB13 are associated with the highest increase in prostate cancer risk, and BRCA2 mutations are also linked to more aggressive disease. The prevalence of these genetic variants increases with disease severity:

• 4.6% in localized prostate cancer (confined to the prostate)
• 11.8% in metastatic disease (spread to other parts of the body)
• 16.2% in metastatic castration-resistant prostate cancer (the most advanced stage)

A large study by Nicolosi and colleagues found a PGV rate of 17.2% among individuals with a history of prostate cancer regardless of disease stage. Broken down by gene, the rates were BRCA2 at 4.74%, CHEK2 at 2.88%, ATM at 2.03%, and BRCA1 at 1.25%.

Here is one of the most important findings for patients: 37% of PGVs occurred in individuals with no family history of prostate cancer at all. This means that if genetic testing were offered only to men with a known family history, more than one-third of men carrying dangerous mutations would be missed.

Polygenic Risk Scores: Many Small Genetic Changes Add Up

Beyond the high-impact single-gene mutations, there are hundreds of small genetic variations called single-nucleotide polymorphisms (SNPs). Genome-wide association studies have identified more than 451 SNPs associated with prostate cancer. When combined, their cumulative effect can be quantified using a polygenic risk score (PRS).

PRS has been shown to improve the detection of clinically significant prostate cancer in prospective studies, complementing standard tools like MRI and PSA testing. However, current genetic testing cannot capture all relevant risk variants. Earlier PRS models based on 269 SNPs captured only 30–40% of familial relative risk. This is why the authors stress that family history must remain a separate risk factor even after genetic testing — a negative genetic test does not erase a strong family history.

The stakes are high. A combination of familial risk, a high PRS, and unfavorable lifestyle factors is associated with a threefold higher risk of death from prostate cancer before the age of 75 years.

Ancestry: A Critical but Under-Recognized Factor

Ancestry significantly modifies prostate cancer risk. The statistics are striking:

• Men of African ancestry have on average a 2.18-fold higher genetic risk of prostate cancer (95% CI 2.14–2.22) compared with men of European ancestry.
• Men of East Asian ancestry have a 0.73-fold lower risk (95% CI 0.71–0.76).

Germline variant prevalence also varies by ancestry. It is highest in Ashkenazi Jewish (22.7%) and White (17.8%) men, and lowest in African American (10.1%) and Hispanic (6.4%) men. However, the picture is complicated: prostate cancer incidence and mortality are actually higher among Black men in the USA, a disparity driven not only by biology but also by social determinants of health, such as health-care availability, access to screening, and other social factors.

Non-White populations remain under-represented in research and germline testing guidelines. This leads to a lower diagnostic yield and higher rates of variants of uncertain significance — genetic changes that doctors cannot yet confidently classify as harmful or harmless. The authors call for inclusive genomic data and ancestry-informed strategies for early detection, a point echoed by recent research on rare pathogenic structural variants in African men and aggressive prostate cancer in men of African ancestry.

Current Gaps in Prostate Cancer Care

Despite growing evidence about genetic and familial risk, the clinical integration of risk-adapted early detection remains very limited. The contrast with breast and ovarian cancer is stark. For those cancers, risk assessment programs and genetic testing are well established. For prostate cancer, significant gaps persist, and the consequences are measurable.

The Gender Gap in Genetic Testing

Several studies highlight substantial gender disparities: women with breast or ovarian cancer are far more likely to undergo genetic testing than men with prostate cancer. The same disparity extends to unaffected relatives. Test results are also communicated to male relatives less often within families, likely because the relevance of female family history (such as a mother's breast cancer or a sister's ovarian cancer) for men's prostate cancer risk is underestimated. Men also report difficulty finding tailored information, underscoring the need for male-focused resources.

Why the underutilization? Researchers point to limited awareness among both patients and clinicians, gender-related social roles, and men's generally lower engagement in preventive care. These are not minor issues — they represent missed opportunities for cascade testing (testing family members of someone with a known mutation) and potential treatment adaptations.

Opportunistic Screening: Skewed and Inefficient

Early detection of prostate cancer remains largely opportunistic in many countries. That means screening happens by chance — when a man happens to see a doctor who orders a PSA test — rather than through a structured program targeting those at highest risk. This leads to a skewed uptake:

• Higher PSA testing rates among wealthier, more educated men
• Lower uptake among minority groups
• Ongoing overdiagnosis and overtreatment, especially in men over age 70

Meanwhile, although guidelines recommend earlier screening for men at high risk of prostate cancer, implementation is mostly confined to research studies. Structured clinical screening pathways and guidance written for patients themselves still need to be developed. There is also no consensus on which precise group of PGVs should be universally considered high-risk and included in intensified screening programs. Finally, insurance coverage for genetic testing varies greatly by region, limiting access even for those with explicit family histories.

The Psychological Side of Genetic Testing

The authors also raise an often-overlooked concern: the potential psychosocial burden of genetic testing in men at high risk of prostate cancer. The IMPACT study, a prospective study of men with BRCA1/2 mutations, found low and largely stable psychosocial distress levels among carriers over time. But a subgroup of carriers did report heightened distress. These men may benefit from tailored psychological screening and support, but such support structures are currently not implemented in regular care.

Genetic counseling must therefore address each patient's individual situation and take into account the potential psychological burden. This also concerns psycho-oncological health care professionals, who are often the first point of contact for distressed patients but may lack specific training in the clinical issues related to genetic testing.

There are signs of movement. Sweden has launched a pilot screening program for risk-adapted early detection, and Germany has issued funding calls for the development and evaluation of risk-based screening algorithms. Governments are beginning to act — but the authors argue that much more is needed.

Recommendations: How Early Detection Should Be Expanded

The authors lay out a comprehensive set of recommendations spanning risk assessment, genetic testing, screening pathways, and education. Their goal is to create a system that proactively reaches high-risk men rather than waiting for them to stumble into screening.

Risk Assessment, Communication, and Awareness

The first step is to define standardized criteria for genetic testing eligibility based on family history and hereditary risk — and these criteria must explicitly include men with prostate cancer. Current guidelines partly overlap but also differ in their definitions, which makes it difficult to compare studies linking family history to PGVs. Standardization would improve both clinical care and research.

The authors recommend that routine risk assessment in primary care should include ancestry and family history of prostate cancer, PGVs, and breast, ovarian, and colorectal cancers. To make this workable, they call for validated, easy-to-use tools for primary care doctors to assess familial cancer history and ancestry — analogous to breast cancer tools such as the Helix Tool. These tools would help identify known genetic variants in a family and facilitate standardized referral to genetic counseling.

For men with prostate cancer who meet genetic testing criteria (based on family history or metastatic disease), the treating urologist or oncologist should initiate referral at diagnosis and before treatment. This timing matters because the results may affect the choice of therapy and trigger cascade testing of family members. Genetic counseling should involve shared decision-making and address ethical, legal, and social aspects.

Expanding Cascade Testing

To expand cascade testing (testing relatives of mutation carriers), the authors recommend targeted education for both providers and patients. This education should correct misconceptions and highlight the importance of PGVs — especially in BRCA1/2 — for male relatives. They also suggest offering family letter templates to PGV carriers to support communication of test results to relatives, along with information on how to access genetic testing. For patients, centralized information materials should be developed in plain, lay language.

The authors acknowledge real-world barriers: the financial burden and the limited availability of trained genetic professionals. But they note that as testing costs continue to decline and resource-sparing models emerge, the value of germline testing is becoming increasingly clear — especially when weighed against the potentially substantial costs of treating advanced prostate cancer.

What a Structured Screening Pathway Looks Like

Implementation of risk-adapted screening pathways for high-risk men is crucial to balance sensitivity (finding real cancers) against overdiagnosis (finding harmless ones). Importantly, the authors emphasize that a negative germline test does not negate the need for intensified screening in men with a positive family history. Family history remains an independent risk factor.

Exact definitions of risk groups and which PGVs to include still need to be established. Prospective trials have demonstrated the clinical utility of risk stratification based on baseline PSA with adjunct MRI in the general population. Growing evidence on PRS and risk calculators may further refine risk stratification. But while validation continues, men at high risk need recommendations now, not after years of additional research.

The article presents two examples of risk-adapted screening protocols. The first comes from Germany's first dedicated clinic for early detection of prostate cancer in men with a family history of cancer or a PGV (trial NCT05681416). It relies on baseline PSA testing and multiparametric MRI (mpMRI) for risk stratification, with the following structure for high-risk individuals aged 45 with no PGVs:

For men aged 40 with PGVs, the same protocol applies, but the screening starts five years earlier. The risk categories are based on PSA level (with <3 ng/ml considered low) and MRI findings using the PI-RADS scoring system (with 1–2 considered low risk and 4–5 considered high risk), combined with the ERSPC Risk Calculator 4 score (with a cutoff of 12%). A second US-based protocol (trial NCT06398639) similarly incorporates a polygenic risk score and relies on MRI and PSA to identify clinically relevant cancers requiring biopsy.

The authors also note that digital rectal examination (DRE) performs poorly as a standalone screening tool and offers no added benefit when combined with PSA testing, based on recent evidence. The European Association of Urology has proposed a screening algorithm for the general population of men aged 50–70 years.

Several cross-cutting recommendations emerge for successful implementation:

• Adequate counseling and shared decision-making about the pros and cons of PSA testing are essential for guideline compliance.
• Policies should ensure that intensified, risk-adapted screening for high-risk men is available without additional out-of-pocket costs, to reduce disparities.
• Specialized, interdisciplinary centers (analogous to breast/ovarian cancer centers) may facilitate the optimal implementation of risk stratification, screening, and counseling as an integrated workflow.
• However, the financial sustainability of such comprehensive prevention centers is a central concern, and this model may not be feasible in many parts of the world. Cost-effectiveness research remains crucial to inform broader adoption in public health-care systems.
• The expansion of screening for high-risk men should align with structured, risk-adapted screening in the general population — beyond routine family history assessment, eligible men should receive invitations to PSA testing, and testing should be performed only when indicated.

Conclusions: A Coordinated Call to Action

The authors argue that even while research continues to investigate best-practice pathways, implementation of intensified screening for high-risk men is needed now. Genetic testing of index patients (the first person in a family identified with a mutation) and appropriate cascade testing should become more broadly available. This testing should use established criteria with validated tools and proceed with standardized referrals to genetic counseling where needed.

Provider and patient education — together with dissemination of information about men's cancer risk and the importance of communicating genetic test results to male relatives — is crucial. Men identified as high risk should be offered risk-adapted prostate cancer screening, possibly through specialized interdisciplinary prostate cancer centers where available.

Finally, the authors call for a coordinated agenda covering research, financing, and implementation to fill the evidence gaps for early detection of high-risk prostate cancer. This will require interdisciplinary collaboration among clinicians, researchers, health insurance companies, regulatory authorities, patient advocates, and industry — working together to align evidence generation, secure sustainable funding, and facilitate successful long-term implementation of early detection programs.

What This Study Could Not Answer

This is a call-to-action paper, not a clinical trial, so it has important limitations that patients should understand:

• The proposed screening pathways are examples, with trial validation pending (NCT05681416 in Germany and NCT06398639 in the USA).
• The optimal risk-stratified screening strategy remains under investigation, particularly with emerging imaging modalities and biomarker-based approaches.
• Current genetic testing does not capture all relevant risk variants — earlier PRS models captured only 30–40% of familial relative risk.
• There is no consensus on which precise PGVs should be included in intensive screening programs.
• Non-White populations are under-represented in genetic research, limiting the applicability of current findings across ethnic groups.
• The psychosocial burden of genetic testing in high-risk men requires further study, since this population remains under-represented in such research.
• The cost-effectiveness of specialized centers and risk-adapted screening programs remains uncertain, and this model may not be feasible in resource-limited settings.

What This Means for You: Practical Steps

If you are a man concerned about prostate cancer risk, this article provides several actionable takeaways. First, know your family history — and not just on your father's side. A family history of breast, ovarian, or colorectal cancer in any relative can also raise your prostate cancer risk.

Second, talk to your doctor about genetic testing if you have a family history of prostate cancer, especially if a first-degree relative was diagnosed at a young age, or if you have metastatic prostate cancer yourself. The 37% of PGVs found in men with no family history mean family history alone is insufficient to guide testing decisions.

Third, understand that ancestry matters. Men of African ancestry face a more than twofold higher genetic risk and should discuss earlier screening with their doctors. Men of Ashkenazi Jewish descent also have a higher prevalence of relevant genetic variants.

Fourth, if you are identified as high risk, expect a structured screening plan that likely includes annual PSA testing and mpMRI, starting at age 40 if you carry a PGV or at age 45 if you have a strong family history. A rising PSA velocity (>0.7 ng/ml/year) should trigger earlier MRI. If you are at intermediate or high risk based on PSA and MRI findings, an MRI/ultrasound fusion biopsy may be recommended.

Finally, participate in shared decision-making with your health-care team. Discuss the pros and cons of testing and screening, and if you carry a genetic variant, share that information with male relatives — it could save their lives too.

Frequently Asked Questions

Who is at high risk for prostate cancer?

High risk includes men with a family history of prostate cancer, especially a father or brother diagnosed young, plus inherited mutations in genes like BRCA2, HOXB13, or Lynch syndrome genes. Men of African ancestry have a 2.18-fold higher genetic risk. A family history of breast, ovarian, or colorectal cancer also raises risk.

I have no family history of prostate cancer. Can I still carry a genetic mutation?

Yes. In one large study, 37% of pathogenic germline variants occurred in men with no family history of prostate cancer. So relying only on family history would miss more than one-third of mutation carriers. Discuss genetic testing with your doctor if you have other risk factors or are concerned.

Should I get genetic testing for prostate cancer risk?

Consider testing if you have metastatic prostate cancer, a family history of prostate cancer (especially early-onset), or a family history of breast, ovarian, or colorectal cancer. Genetic testing can identify mutations in BRCA1/2, HOXB13, and other genes. A negative result does not erase a strong family history—family history remains an independent risk factor.

How does ancestry affect my prostate cancer risk?

Men of African ancestry have about a 2.18-fold higher genetic risk compared to European ancestry. Men of East Asian ancestry have a 0.73-fold lower risk. Germline variant prevalence is highest in Ashkenazi Jewish (22.7%) and White (17.8%) men, lower in African American (10.1%) and Hispanic (6.4%) men. Non-White populations are under-represented in research.

If I am at high risk, what screening plan should I expect?

A structured plan may start at age 40 if you carry a pathogenic variant, or age 45 with strong family history. It typically includes annual PSA and mpMRI. Intermediate or high risk based on PSA, MRI, and risk calculator scores may lead to MRI/ultrasound fusion biopsy. Rising PSA velocity over 0.7 ng/ml/year triggers earlier MRI.

Can genetic testing cause psychological distress?

The IMPACT study of men with BRCA1/2 mutations found low and largely stable distress over time, but a subgroup did report heightened distress. Genetic counseling should address individual situations and potential psychological burden. Psycho-oncological professionals may be the first contact for distressed patients but may need specific training in genetic testing issues.

What practical steps can I take to assess my prostate cancer risk?

Know your full family history, including breast, ovarian, and colorectal cancer on both sides. Talk to your doctor about genetic testing if you have a family history or metastatic disease. Understand your ancestry's impact. If high risk, expect annual PSA and mpMRI starting at age 40–45. Share genetic results with male relatives—it could save lives.

Source Information

Original article title: Expanding Risk-adapted Early Detection of Prostate Cancer- A Call to Action for Men at High Risk

Authors: Maike K. Klett, Peter Albers, Adam Kibel, Jale Lakes, Huma Q. Rana, Michael Serzan, André Karger, Alicia K. Morgans

Journal: European Urology Oncology, 2026 (DOI: 10.1016/j.euo.2026.01.012)

Affiliations: Heinrich-Heine-University Düsseldorf (Germany), Dana-Farber Cancer Institute / Harvard Medical School (Boston, USA), German Cancer Research Center (Heidelberg, Germany), Mass General Brigham / Harvard Medical School (Boston, USA)

Note: This patient-friendly article is based on peer-reviewed research published as an open-access article under the CC BY license. It is intended for educational purposes and does not replace individualized medical advice. Always discuss your personal prostate cancer risk with a qualified healthcare professional.